25 XP   0   0   10

China Resources Double-Crane Pharmaceutical Co Ltd
Buy, Hold or Sell?

Let's analyse China Resources Double-Crane Pharmaceutical Co Ltd together

PenkeI guess you are interested in China Resources Double-Crane Pharmaceutical Co Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of China Resources Double-Crane Pharmaceutical Co Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about China Resources Double-Crane Pharmaceutical Co Ltd

I send you an email if I find something interesting about China Resources Double-Crane Pharmaceutical Co Ltd.

Quick analysis of China Resources Double-Crane Pharmaceutical Co Ltd (30 sec.)










What can you expect buying and holding a share of China Resources Double-Crane Pharmaceutical Co Ltd? (30 sec.)

How much money do you get?

How much money do you get?
¥0.04
When do you have the money?
1 year
How often do you get paid?
87.5%

What is your share worth?

Current worth
¥11.34
Expected worth in 1 year
¥12.39
How sure are you?
95.0%

+ What do you gain per year?

Total Gains per Share
¥1.36
Return On Investment
6.5%

For what price can you sell your share?

Current Price per Share
¥20.99
Expected price per share
¥18.93 - ¥24.43
How sure are you?
50%

1. Valuation of China Resources Double-Crane Pharmaceutical Co Ltd (5 min.)




Live pricePrice per Share (EOD)

¥20.99

Intrinsic Value Per Share

¥6.88 - ¥19.47

Total Value Per Share

¥18.22 - ¥30.81

2. Growth of China Resources Double-Crane Pharmaceutical Co Ltd (5 min.)




Is China Resources Double-Crane Pharmaceutical Co Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$1.6b$1.4b$118m7.5%

How much money is China Resources Double-Crane Pharmaceutical Co Ltd making?

Current yearPrevious yearGrowGrow %
Making money$46m$40.1m$5.8m12.7%
Net Profit Margin13.1%12.2%--

How much money comes from the company's main activities?

3. Financial Health of China Resources Double-Crane Pharmaceutical Co Ltd (5 min.)




What can you expect buying and holding a share of China Resources Double-Crane Pharmaceutical Co Ltd? (5 min.)

Welcome investor! China Resources Double-Crane Pharmaceutical Co Ltd's management wants to use your money to grow the business. In return you get a share of China Resources Double-Crane Pharmaceutical Co Ltd.

What can you expect buying and holding a share of China Resources Double-Crane Pharmaceutical Co Ltd?

First you should know what it really means to hold a share of China Resources Double-Crane Pharmaceutical Co Ltd. And how you can make/lose money.

Speculation

The Price per Share of China Resources Double-Crane Pharmaceutical Co Ltd is ¥20.99. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of China Resources Double-Crane Pharmaceutical Co Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in China Resources Double-Crane Pharmaceutical Co Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ¥11.34. Based on the TTM, the Book Value Change Per Share is ¥0.26 per quarter. Based on the YOY, the Book Value Change Per Share is ¥0.06 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ¥0.08 per quarter.
Based on historical numbers we can estimate the returns while holding a share of China Resources Double-Crane Pharmaceutical Co Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share
Usd Eps0.030.2%0.050.2%0.050.2%0.040.2%0.030.2%
Usd Book Value Change Per Share0.030.2%0.040.2%0.010.0%0.030.1%0.020.1%
Usd Dividend Per Share0.020.1%0.010.1%0.030.2%0.020.1%0.020.1%
Usd Total Gains Per Share0.060.3%0.050.2%0.040.2%0.050.2%0.040.2%
Usd Price Per Share2.57-2.44-2.70-2.07-2.49-
Price to Earnings Ratio18.94-14.09-14.50-16.82-24.78-
Price-to-Total Gains Ratio45.18-66.94-97.34-84.86-69.90-
Price to Book Ratio1.64-1.61-1.93-1.56-2.43-
Price-to-Total Gains Ratio45.18-66.94-97.34-84.86-69.90-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.898719
Number of shares344
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.010.02
Usd Book Value Change Per Share0.040.03
Usd Total Gains Per Share0.050.05
Gains per Quarter (344 shares)16.1516.59
Gains per Year (344 shares)64.6166.35
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1155055313556
2291001206271122
34415018593106188
458200250124142254
573250315154177320
687300380185213386
7102350445216248452
8117400510247284518
9131450575278319584
10146500640309355650

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%40.00.00.0100.0%85.00.03.096.6%
Book Value Change Per Share4.00.00.0100.0%11.01.00.091.7%18.02.00.090.0%36.04.00.090.0%73.015.00.083.0%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%35.00.05.087.5%65.00.023.073.9%
Total Gains per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%38.02.00.095.0%78.010.00.088.6%

Fundamentals of China Resources Double-Crane Pharmaceutical Co Ltd

About China Resources Double-Crane Pharmaceutical Co Ltd

China Resources Double-Crane Pharmaceutical Co.,Ltd., together with its subsidiaries, operates as a pharmaceutical company in the People's Republic of China. The company offers pharmaceutical products for hypertension, diabetes, hypercholesterolemia, gastrointestinal care, and pediatric care, as well as peritoneal dialysis solution. It also provides injections for acute craniocerebral trauma, viral pneumonia and bronchitis, infectious diseases, calcium deficiency, metabolic acidosis, vitamin B and C deficiency, chronic severe pain, drug-resistant bacteria, and hypovolemia. In addition, the company offers pharmaceutical raw materials; pharmaceutical equipment comprising aluminum-plastic blister packaging machine and multifunctional cartoning machine. The company was founded in 1939 and is headquartered in Beijing, the People's Republic of China. China Resources Double-Crane Pharmaceutical Co.,Ltd. is a subsidiary of China Resources Pharmaceutical Group Limited.

Fundamental data was last updated by Penke on 2024-04-17 04:59:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is underpriced.
Based on how much money comes from the company's main activities, the company is overpriced.

1.1. Profitability of China Resources Double-Crane Pharmaceutical Co Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit China Resources Double-Crane Pharmaceutical Co Ltd earns for each ¥1 of revenue.

  • Above 10% is considered healthy but always compare China Resources Double-Crane Pharmaceutical Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 9.5% means that ¥0.10 for each ¥1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of China Resources Double-Crane Pharmaceutical Co Ltd:

  • The MRQ is 9.5%. The company is making a profit. +1
  • The TTM is 13.1%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ9.5%TTM13.1%-3.6%
TTM13.1%YOY12.2%+0.9%
TTM13.1%5Y11.7%+1.4%
5Y11.7%10Y12.2%-0.5%
1.1.2. Return on Assets

Shows how efficient China Resources Double-Crane Pharmaceutical Co Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare China Resources Double-Crane Pharmaceutical Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • 1.7% Return on Assets means that China Resources Double-Crane Pharmaceutical Co Ltd generated ¥0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of China Resources Double-Crane Pharmaceutical Co Ltd:

  • The MRQ is 1.7%. Using its assets, the company is less efficient in making profit.
  • The TTM is 2.2%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ1.7%TTM2.2%-0.6%
TTM2.2%YOY2.1%+0.1%
TTM2.2%5Y2.1%+0.1%
5Y2.1%10Y2.2%-0.1%
1.1.3. Return on Equity

Shows how efficient China Resources Double-Crane Pharmaceutical Co Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare China Resources Double-Crane Pharmaceutical Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • 2.3% Return on Equity means China Resources Double-Crane Pharmaceutical Co Ltd generated ¥0.02 for each ¥1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of China Resources Double-Crane Pharmaceutical Co Ltd:

  • The MRQ is 2.3%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 3.1%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ2.3%TTM3.1%-0.8%
TTM3.1%YOY2.9%+0.2%
TTM3.1%5Y2.9%+0.2%
5Y2.9%10Y2.9%+0.0%

1.2. Operating Efficiency of China Resources Double-Crane Pharmaceutical Co Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient China Resources Double-Crane Pharmaceutical Co Ltd is operating .

  • Measures how much profit China Resources Double-Crane Pharmaceutical Co Ltd makes for each ¥1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare China Resources Double-Crane Pharmaceutical Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated ¥0.00  for each ¥1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of China Resources Double-Crane Pharmaceutical Co Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM4.1%-4.1%
TTM4.1%YOY7.5%-3.5%
TTM4.1%5Y10.2%-6.1%
5Y10.2%10Y6.0%+4.2%
1.2.2. Operating Ratio

Measures how efficient China Resources Double-Crane Pharmaceutical Co Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.34 means that the operating costs are ¥1.34 for each ¥1 in net sales.

Let's take a look of the Operating Ratio trends of China Resources Double-Crane Pharmaceutical Co Ltd:

  • The MRQ is 1.344. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.296. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.344TTM1.296+0.048
TTM1.296YOY1.311-0.015
TTM1.2965Y1.277+0.019
5Y1.27710Y0.913+0.364

1.3. Liquidity of China Resources Double-Crane Pharmaceutical Co Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if China Resources Double-Crane Pharmaceutical Co Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 2.42 means the company has ¥2.42 in assets for each ¥1 in short-term debts.

Let's take a look of the Current Ratio trends of China Resources Double-Crane Pharmaceutical Co Ltd:

  • The MRQ is 2.416. The company is able to pay all its short-term debts. +1
  • The TTM is 2.456. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.416TTM2.456-0.041
TTM2.456YOY2.476-0.020
TTM2.4565Y2.554-0.098
5Y2.55410Y1.455+1.099
1.3.2. Quick Ratio

Measures if China Resources Double-Crane Pharmaceutical Co Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare China Resources Double-Crane Pharmaceutical Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.49 means the company can pay off ¥0.49 for each ¥1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of China Resources Double-Crane Pharmaceutical Co Ltd:

  • The MRQ is 0.494. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.715. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.494TTM0.715-0.221
TTM0.715YOY0.727-0.012
TTM0.7155Y0.927-0.212
5Y0.92710Y1.251-0.324

1.4. Solvency of China Resources Double-Crane Pharmaceutical Co Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of China Resources Double-Crane Pharmaceutical Co Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare China Resources Double-Crane Pharmaceutical Co Ltd to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.24 means that China Resources Double-Crane Pharmaceutical Co Ltd assets are financed with 23.6% credit (debt) and the remaining percentage (100% - 23.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of China Resources Double-Crane Pharmaceutical Co Ltd:

  • The MRQ is 0.236. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.243. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.236TTM0.243-0.007
TTM0.243YOY0.255-0.012
TTM0.2435Y0.242+0.001
5Y0.24210Y0.205+0.037
1.4.2. Debt to Equity Ratio

Measures if China Resources Double-Crane Pharmaceutical Co Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare China Resources Double-Crane Pharmaceutical Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 32.8% means that company has ¥0.33 debt for each ¥1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of China Resources Double-Crane Pharmaceutical Co Ltd:

  • The MRQ is 0.328. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.342. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.328TTM0.342-0.014
TTM0.342YOY0.365-0.023
TTM0.3425Y0.333+0.009
5Y0.33310Y0.272+0.061

2. Market Valuation of China Resources Double-Crane Pharmaceutical Co Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ¥1 in earnings China Resources Double-Crane Pharmaceutical Co Ltd generates.

  • Above 15 is considered overpriced but always compare China Resources Double-Crane Pharmaceutical Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 18.94 means the investor is paying ¥18.94 for every ¥1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of China Resources Double-Crane Pharmaceutical Co Ltd:

  • The EOD is 21.374. Based on the earnings, the company is fair priced.
  • The MRQ is 18.941. Based on the earnings, the company is fair priced.
  • The TTM is 14.093. Based on the earnings, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD21.374MRQ18.941+2.434
MRQ18.941TTM14.093+4.847
TTM14.093YOY14.497-0.403
TTM14.0935Y16.820-2.727
5Y16.82010Y24.780-7.960
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of China Resources Double-Crane Pharmaceutical Co Ltd:

  • The EOD is 15.206. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 13.475. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 56.186. Based on how much money comes from the company's main activities, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD15.206MRQ13.475+1.731
MRQ13.475TTM56.186-42.712
TTM56.186YOY59.465-3.278
TTM56.1865Y31.845+24.341
5Y31.84510Y10.390+21.455
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of China Resources Double-Crane Pharmaceutical Co Ltd is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of China Resources Double-Crane Pharmaceutical Co Ltd:

  • The EOD is 1.851. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.640. Based on the equity, the company is underpriced. +1
  • The TTM is 1.612. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.851MRQ1.640+0.211
MRQ1.640TTM1.612+0.029
TTM1.612YOY1.930-0.318
TTM1.6125Y1.563+0.048
5Y1.56310Y2.428-0.864
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of China Resources Double-Crane Pharmaceutical Co Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.2370.263-10%0.061+289%0.187+27%0.155+52%
Book Value Per Share--11.33910.969+3%10.131+12%9.563+19%8.041+41%
Current Ratio--2.4162.456-2%2.476-2%2.554-5%1.455+66%
Debt To Asset Ratio--0.2360.243-3%0.255-7%0.242-2%0.205+15%
Debt To Equity Ratio--0.3280.342-4%0.365-10%0.333-1%0.272+21%
Dividend Per Share--0.1750.077+128%0.240-27%0.163+8%0.121+45%
Eps--0.2460.328-25%0.349-30%0.279-12%0.229+7%
Free Cash Flow Per Share--0.3450.246+40%0.196+76%0.235+47%0.293+18%
Free Cash Flow To Equity Per Share--0.3450.237+46%0.058+494%0.144+140%0.228+51%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--19.468--------
Intrinsic Value_10Y_min--6.882--------
Intrinsic Value_1Y_max--1.287--------
Intrinsic Value_1Y_min--0.837--------
Intrinsic Value_3Y_max--4.373--------
Intrinsic Value_3Y_min--2.402--------
Intrinsic Value_5Y_max--8.069--------
Intrinsic Value_5Y_min--3.832--------
Market Cap21822464071.680+11%19339164018.60018412068442.665+5%20379275658.350-5%15622070804.758+24%18798955330.954+3%
Net Profit Margin--0.0950.131-27%0.122-22%0.117-18%0.122-22%
Operating Margin---0.041-100%0.075-100%0.102-100%0.060-100%
Operating Ratio--1.3441.296+4%1.311+3%1.277+5%0.913+47%
Pb Ratio1.851+11%1.6401.612+2%1.930-15%1.563+5%2.428-32%
Pe Ratio21.374+11%18.94114.093+34%14.497+31%16.820+13%24.780-24%
Price Per Share20.990+11%18.60017.680+5%19.535-5%14.988+24%18.057+3%
Price To Free Cash Flow Ratio15.206+11%13.47556.186-76%59.465-77%31.845-58%10.390+30%
Price To Total Gains Ratio50.987+11%45.18166.941-33%97.339-54%84.863-47%69.902-35%
Quick Ratio--0.4940.715-31%0.727-32%0.927-47%1.251-61%
Return On Assets--0.0170.022-25%0.021-20%0.021-21%0.022-24%
Return On Equity--0.0230.031-26%0.029-22%0.029-20%0.029-19%
Total Gains Per Share--0.4120.340+21%0.301+37%0.349+18%0.276+49%
Usd Book Value--1628167592.4171577564859.920+3%1459504002.315+12%1376531678.790+18%1156616853.210+41%
Usd Book Value Change Per Share--0.0330.036-10%0.008+289%0.026+27%0.021+52%
Usd Book Value Per Share--1.5661.515+3%1.399+12%1.321+19%1.111+41%
Usd Dividend Per Share--0.0240.011+128%0.033-27%0.022+8%0.017+45%
Usd Eps--0.0340.045-25%0.048-30%0.039-12%0.032+7%
Usd Free Cash Flow--49551613.64435433440.849+40%28177091.244+76%33847693.713+46%42152360.791+18%
Usd Free Cash Flow Per Share--0.0480.034+40%0.027+76%0.032+47%0.040+18%
Usd Free Cash Flow To Equity Per Share--0.0480.033+46%0.008+494%0.020+140%0.032+51%
Usd Market Cap3013682288.299+11%2670738550.9692542706651.932+5%2814377968.418-5%2157407978.137+24%2596135731.205+3%
Usd Price Per Share2.899+11%2.5692.442+5%2.698-5%2.070+24%2.494+3%
Usd Profit--35251294.98346022842.518-23%40175002.973-12%37926747.651-7%31835634.241+11%
Usd Revenue--369588307.738352919111.036+5%326155094.848+13%322225294.510+15%263173060.601+40%
Usd Total Gains Per Share--0.0570.047+21%0.042+37%0.048+18%0.038+49%
 EOD+4 -4MRQTTM+19 -16YOY+18 -175Y+21 -1410Y+24 -11

3.2. Fundamental Score

Let's check the fundamental score of China Resources Double-Crane Pharmaceutical Co Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1521.374
Price to Book Ratio (EOD)Between0-11.851
Net Profit Margin (MRQ)Greater than00.095
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.494
Current Ratio (MRQ)Greater than12.416
Debt to Asset Ratio (MRQ)Less than10.236
Debt to Equity Ratio (MRQ)Less than10.328
Return on Equity (MRQ)Greater than0.150.023
Return on Assets (MRQ)Greater than0.050.017
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of China Resources Double-Crane Pharmaceutical Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5056.075
Ma 20Greater thanMa 5020.493
Ma 50Greater thanMa 10020.157
Ma 100Greater thanMa 20019.287
OpenGreater thanClose21.300
Total5/5 (100.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in CNY. All numbers in thousands.

Summary
Total Assets15,430,960
Total Liabilities3,641,187
Total Stockholder Equity11,090,411
 As reported
Total Liabilities 3,641,187
Total Stockholder Equity+ 11,090,411
Total Assets = 15,430,960

Assets

Total Assets15,430,960
Total Current Assets7,638,487
Long-term Assets7,792,473
Total Current Assets
Cash And Cash Equivalents 3,457,023
Net Receivables 1,561,264
Inventory 1,562,447
Other Current Assets 44,034
Total Current Assets  (as reported)7,638,487
Total Current Assets  (calculated)6,624,769
+/- 1,013,718
Long-term Assets
Property Plant Equipment 3,810,170
Goodwill 906,058
Intangible Assets 2,482,260
Long-term Assets Other 42,316
Long-term Assets  (as reported)7,792,473
Long-term Assets  (calculated)7,240,805
+/- 551,668

Liabilities & Shareholders' Equity

Total Current Liabilities3,162,113
Long-term Liabilities479,074
Total Stockholder Equity11,090,411
Total Current Liabilities
Short Long Term Debt 29,969
Accounts payable 722,509
Other Current Liabilities 20,799
Total Current Liabilities  (as reported)3,162,113
Total Current Liabilities  (calculated)773,277
+/- 2,388,836
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt29,950
Long-term Liabilities Other 1,667
Long-term Liabilities  (as reported)479,074
Long-term Liabilities  (calculated)31,617
+/- 447,457
Total Stockholder Equity
Retained Earnings 9,670,626
Total Stockholder Equity (as reported)11,090,411
Total Stockholder Equity (calculated)9,670,626
+/- 1,419,786
Other
Capital Stock1,039,740
Common Stock Shares Outstanding 1,039,740
Net Invested Capital 11,120,380
Net Working Capital 4,476,373
Property Plant and Equipment Gross 3,810,170



Balance Sheet

Currency in CNY. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-06-302000-12-312000-06-30
> Total Assets 
1,372,527
1,484,156
2,120,531
2,746,287
3,342,277
3,451,172
3,480,371
3,616,465
3,775,679
3,830,385
4,383,031
4,257,868
4,892,502
4,180,432
4,089,724
4,025,260
3,953,802
4,150,099
4,178,666
3,813,294
3,657,601
3,442,493
3,412,787
3,259,320
3,431,692
3,481,576
3,591,459
3,673,463
3,929,502
4,321,363
4,388,331
4,269,022
4,465,183
4,571,899
4,686,601
4,716,975
4,988,842
5,045,398
5,171,354
5,205,509
5,686,318
5,755,333
5,901,657
6,076,968
6,429,780
6,434,699
6,519,758
6,507,776
7,015,154
7,214,953
7,287,800
6,480,916
6,394,979
6,526,307
6,450,298
6,619,296
6,726,340
6,823,862
6,866,928
7,763,107
7,851,641
8,088,512
8,080,397
8,241,550
9,529,960
9,106,357
9,289,040
9,437,896
9,955,512
9,825,787
10,257,421
10,306,171
10,950,123
10,969,088
11,218,418
11,276,865
11,560,742
11,872,222
12,012,007
12,416,487
13,245,137
13,438,855
13,382,910
13,676,050
13,713,458
13,926,684
14,629,515
14,482,537
14,754,931
15,126,706
15,047,463
15,430,960
15,430,96015,047,46315,126,70614,754,93114,482,53714,629,51513,926,68413,713,45813,676,05013,382,91013,438,85513,245,13712,416,48712,012,00711,872,22211,560,74211,276,86511,218,41810,969,08810,950,12310,306,17110,257,4219,825,7879,955,5129,437,8969,289,0409,106,3579,529,9608,241,5508,080,3978,088,5127,851,6417,763,1076,866,9286,823,8626,726,3406,619,2966,450,2986,526,3076,394,9796,480,9167,287,8007,214,9537,015,1546,507,7766,519,7586,434,6996,429,7806,076,9685,901,6575,755,3335,686,3185,205,5095,171,3545,045,3984,988,8424,716,9754,686,6014,571,8994,465,1834,269,0224,388,3314,321,3633,929,5023,673,4633,591,4593,481,5763,431,6923,259,3203,412,7873,442,4933,657,6013,813,2944,178,6664,150,0993,953,8024,025,2604,089,7244,180,4324,892,5024,257,8684,383,0313,830,3853,775,6793,616,4653,480,3713,451,1723,342,2772,746,2872,120,5311,484,1561,372,527
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,008,692
5,127,949
5,135,217
5,778,854
5,770,170
5,992,107
6,038,706
6,331,390
6,583,506
6,672,198
6,800,269
7,498,011
7,454,947
7,356,240
7,522,582
7,474,608
7,596,594
7,403,910
7,164,961
7,442,019
7,697,367
7,563,781
7,638,487
7,638,4877,563,7817,697,3677,442,0197,164,9617,403,9107,596,5947,474,6087,522,5827,356,2407,454,9477,498,0116,800,2696,672,1986,583,5066,331,3906,038,7065,992,1075,770,1705,778,8545,135,2175,127,9495,008,692000000000000000000000000000000000000000000000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,610,658
1,109,854
1,097,016
1,298,788
1,761,615
1,723,769
1,843,915
2,369,512
2,744,424
2,272,132
2,410,281
2,644,939
2,753,017
2,497,055
2,834,035
2,713,588
3,597,589
2,705,733
2,630,251
2,450,545
2,441,826
2,961,560
3,457,023
3,457,0232,961,5602,441,8262,450,5452,630,2512,705,7333,597,5892,713,5882,834,0352,497,0552,753,0172,644,9392,410,2812,272,1322,744,4242,369,5121,843,9151,723,7691,761,6151,298,7881,097,0161,109,8541,610,658000000000000000000000000000000000000000000000000000000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
152,118
791,250
130,215
777,472
557,622
954,840
758,137
553,002
551,654
958,536
851,950
703,763
810,069
958,334
803,583
804,606
100,848
402,132
200,487
401,772
802,761
400,953
0
0400,953802,761401,772200,487402,132100,848804,606803,583958,334810,069703,763851,950958,536551,654553,002758,137954,840557,622777,472130,215791,250152,118000000000000000000000000000000000000000000000000000000000000000000000
       Net Receivables 
230,379
296,911
479,096
627,520
856,246
932,322
937,313
968,359
1,109,679
1,095,544
1,439,591
1,205,924
1,411,427
1,139,354
1,139,220
986,819
1,071,215
1,043,161
1,116,894
841,952
980,234
794,203
879,864
734,627
856,699
831,016
904,962
982,265
1,200,850
1,086,870
1,072,219
790,988
948,694
976,851
1,147,252
1,086,967
1,438,915
1,152,424
1,372,556
1,199,457
1,439,058
1,556,627
1,766,412
1,633,254
1,943,469
1,881,398
2,093,246
1,720,017
2,058,873
2,140,153
2,181,164
1,726,018
1,703,242
1,545,480
1,465,186
1,278,276
1,385,952
1,356,221
1,328,211
1,636,625
1,757,486
1,902,827
1,861,203
1,782,750
1,924,762
1,767,093
1,895,800
1,813,680
2,115,817
1,934,362
2,039,742
1,931,399
1,467,592
1,353,586
1,428,123
2,054,386
2,073,555
1,982,121
2,157,783
2,136,530
2,244,402
2,146,235
2,143,045
2,044,366
1,496,814
2,159,209
2,298,049
1,287,479
1,700,345
2,357,694
1,676,675
1,561,264
1,561,2641,676,6752,357,6941,700,3451,287,4792,298,0492,159,2091,496,8142,044,3662,143,0452,146,2352,244,4022,136,5302,157,7831,982,1212,073,5552,054,3861,428,1231,353,5861,467,5921,931,3992,039,7421,934,3622,115,8171,813,6801,895,8001,767,0931,924,7621,782,7501,861,2031,902,8271,757,4861,636,6251,328,2111,356,2211,385,9521,278,2761,465,1861,545,4801,703,2421,726,0182,181,1642,140,1532,058,8731,720,0172,093,2461,881,3981,943,4691,633,2541,766,4121,556,6271,439,0581,199,4571,372,5561,152,4241,438,9151,086,9671,147,252976,851948,694790,9881,072,2191,086,8701,200,850982,265904,962831,016856,699734,627879,864794,203980,234841,9521,116,8941,043,1611,071,215986,8191,139,2201,139,3541,411,4271,205,9241,439,5911,095,5441,109,679968,359937,313932,322856,246627,520479,096296,911230,379
       Other Current Assets 
30,813
42,635
54,342
93,624
93,769
87,024
121,480
114,450
93,586
121,408
149,641
99,987
104,375
96,716
96,506
92,771
100,800
100,370
136,135
116,217
116,522
111,225
146,549
166,518
181,011
152,403
193,215
145,531
195,978
185,337
237,528
258,503
330,443
340,798
299,586
158,995
211,174
201,539
310,100
227,485
328,613
369,497
352,725
258,218
275,884
225,376
307,997
387,718
436,324
372,638
421,421
179,013
208,908
216,685
658,041
122,735
809,912
176,810
810,514
127,158
493,792
114,008
437,360
123,134
434,958
142,902
730,022
99,392
818,320
153,101
233,420
113,547
449,473
321,732
18,156
136,175
262,401
113,898
154,370
112,216
428,532
178,976
167,613
174,555
56,963
214,572
226,500
92,831
64,270
222,321
18,174
44,034
44,03418,174222,32164,27092,831226,500214,57256,963174,555167,613178,976428,532112,216154,370113,898262,401136,17518,156321,732449,473113,547233,420153,101818,32099,392730,022142,902434,958123,134437,360114,008493,792127,158810,514176,810809,912122,735658,041216,685208,908179,013421,421372,638436,324387,718307,997225,376275,884258,218352,725369,497328,613227,485310,100201,539211,174158,995299,586340,798330,443258,503237,528185,337195,978145,531193,215152,403181,011166,518146,549111,225116,522116,217136,135100,370100,80092,77196,50696,716104,37599,987149,641121,40893,586114,450121,48087,02493,76993,62454,34242,63530,813
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,171,269
5,198,918
5,226,311
5,238,159
5,229,352
5,288,717
5,339,809
5,616,217
5,747,126
5,983,907
6,026,670
6,153,468
6,238,849
6,330,090
7,225,605
7,317,576
7,312,912
7,429,339
7,483,682
7,792,473
7,792,4737,483,6827,429,3397,312,9127,317,5767,225,6056,330,0906,238,8496,153,4686,026,6705,983,9075,747,1265,616,2175,339,8095,288,7175,229,3525,238,1595,226,3115,198,9185,171,269000000000000000000000000000000000000000000000000000000000000000000000000
       Property Plant Equipment 
355,323
452,362
697,215
912,880
1,036,018
1,061,074
1,095,050
1,120,397
1,152,747
1,211,181
1,377,076
1,538,692
1,729,407
1,562,248
1,563,750
1,552,150
1,546,951
1,589,193
1,541,439
1,543,778
1,331,042
1,358,006
1,361,642
1,299,135
71,881
1,220,849
1,127,765
1,107,464
1,034,348
1,284,538
1,181,576
1,325,406
1,245,135
1,377,946
1,343,858
1,560,886
1,412,988
1,560,119
1,426,454
1,688,159
1,598,185
1,790,157
1,649,573
1,995,320
1,903,607
2,130,830
1,952,929
2,208,499
2,039,741
2,245,327
2,071,842
2,213,300
2,014,379
2,032,755
2,013,454
2,053,610
2,056,605
2,036,287
2,016,024
2,444,172
2,478,367
2,424,930
2,390,210
2,361,371
2,488,222
2,486,622
2,456,432
2,449,644
2,422,215
2,416,583
2,660,967
2,632,455
2,603,378
2,619,586
2,612,413
2,621,755
2,603,301
2,633,046
2,639,087
2,672,988
2,880,378
2,882,007
2,900,408
2,957,081
0
2,999,664
3,468,672
3,506,601
3,518,972
3,573,339
3,670,906
3,810,170
3,810,1703,670,9063,573,3393,518,9723,506,6013,468,6722,999,66402,957,0812,900,4082,882,0072,880,3782,672,9882,639,0872,633,0462,603,3012,621,7552,612,4132,619,5862,603,3782,632,4552,660,9672,416,5832,422,2152,449,6442,456,4322,486,6222,488,2222,361,3712,390,2102,424,9302,478,3672,444,1722,016,0242,036,2872,056,6052,053,6102,013,4542,032,7552,014,3792,213,3002,071,8422,245,3272,039,7412,208,4991,952,9292,130,8301,903,6071,995,3201,649,5731,790,1571,598,1851,688,1591,426,4541,560,1191,412,9881,560,8861,343,8581,377,9461,245,1351,325,4061,181,5761,284,5381,034,3481,107,4641,127,7651,220,84971,8811,299,1351,361,6421,358,0061,331,0421,543,7781,541,4391,589,1931,546,9511,552,1501,563,7501,562,2481,729,4071,538,6921,377,0761,211,1811,152,7471,120,3971,095,0501,061,0741,036,018912,880697,215452,362355,323
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
109,509
109,509
109,509
109,509
109,509
109,509
109,509
391,701
391,701
391,701
391,701
391,701
796,995
796,995
796,995
796,995
796,995
796,995
837,955
864,371
864,371
864,371
864,371
839,833
839,833
839,833
839,833
796,412
844,867
844,867
844,867
788,187
788,187
788,187
934,244
934,958
934,958
934,958
934,958
906,058
906,058934,958934,958934,958934,958934,244788,187788,187788,187844,867844,867844,867796,412839,833839,833839,833839,833864,371864,371864,371864,371837,955796,995796,995796,995796,995796,995796,995391,701391,701391,701391,701391,701109,509109,509109,509109,509109,509109,509109,5090000000000000000000000000000000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
160,129
17,900
22,808
22,757
25,612
29,717
34,270
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000034,27029,71725,61222,75722,80817,900160,129000000000000000000000000000000000000000000000000000000000000000000000
       Intangible Assets 
59,019
60,298
57,390
45,231
82,646
81,398
80,197
75,868
76,588
95,156
95,001
78,531
81,300
79,360
79,128
74,888
72,790
31,577
68,796
53,811
44,190
25,932
47,286
40,130
127,989
33,378
141,904
33,985
164,608
39,074
175,770
29,257
159,481
32,557
175,986
51,076
219,604
50,605
231,485
52,520
274,510
46,459
365,004
54,758
418,693
144,407
427,078
40,762
469,128
47,876
498,858
45,121
347,226
352,337
347,429
343,064
343,997
339,806
335,210
1,167,571
1,156,390
1,183,671
1,174,119
1,170,401
1,787,376
1,793,649
1,778,948
1,765,471
1,754,099
944,258
1,092,597
1,053,940
1,550,864
1,177,655
1,620,201
1,637,408
1,643,906
1,667,599
1,690,625
1,650,732
1,799,201
1,765,086
1,774,839
1,899,478
1,972,050
1,979,717
2,227,834
2,281,001
2,285,724
2,329,302
2,301,951
2,482,260
2,482,2602,301,9512,329,3022,285,7242,281,0012,227,8341,979,7171,972,0501,899,4781,774,8391,765,0861,799,2011,650,7321,690,6251,667,5991,643,9061,637,4081,620,2011,177,6551,550,8641,053,9401,092,597944,2581,754,0991,765,4711,778,9481,793,6491,787,3761,170,4011,174,1191,183,6711,156,3901,167,571335,210339,806343,997343,064347,429352,337347,22645,121498,85847,876469,12840,762427,078144,407418,69354,758365,00446,459274,51052,520231,48550,605219,60451,076175,98632,557159,48129,257175,77039,074164,60833,985141,90433,378127,98940,13047,28625,93244,19053,81168,79631,57772,79074,88879,12879,36081,30078,53195,00195,15676,58875,86880,19781,39882,64645,23157,39060,29859,019
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
30,665
33,469
15,752
17,501
25,332
40,986
2,679,330
2,691,036
36,051
48,175
59,850
58,865
62,286
70,840
79,546
51,561
35,894
55,948
44,023
42,316
42,31644,02355,94835,89451,56179,54670,84062,28658,86559,85048,17536,0512,691,0362,679,33040,98625,33217,50115,75233,46930,665000000000000000000000000000000000000000000000000000000000000000000000000
> Total Liabilities 
589,199
628,885
1,153,071
1,256,281
1,840,552
1,887,181
1,869,459
2,011,551
2,127,004
2,112,690
2,562,540
2,541,237
3,111,986
2,462,865
2,358,377
2,297,934
2,188,802
2,270,366
2,257,357
1,874,026
1,733,011
1,462,651
1,464,390
1,264,114
1,346,969
1,401,727
1,440,176
1,308,775
1,452,511
1,371,147
1,348,199
1,118,559
1,171,301
1,247,020
1,249,107
1,182,188
1,278,109
1,355,051
1,342,085
1,279,581
1,569,141
1,662,969
1,700,164
1,733,667
1,867,609
1,974,324
1,918,484
1,801,041
2,147,730
2,354,639
2,242,316
1,144,690
908,278
1,069,390
878,713
934,926
872,025
806,111
750,541
1,329,199
1,232,943
1,344,588
1,161,677
1,203,051
2,246,832
1,596,694
1,564,814
1,589,333
1,794,040
2,336,985
2,468,033
2,397,575
2,708,574
2,708,192
2,673,359
2,600,306
2,607,973
2,952,478
2,770,601
3,039,501
3,126,770
3,302,205
2,943,796
3,199,499
3,177,908
3,436,734
4,110,829
3,752,891
3,636,941
3,884,932
3,503,593
3,641,187
3,641,1873,503,5933,884,9323,636,9413,752,8914,110,8293,436,7343,177,9083,199,4992,943,7963,302,2053,126,7703,039,5012,770,6012,952,4782,607,9732,600,3062,673,3592,708,1922,708,5742,397,5752,468,0332,336,9851,794,0401,589,3331,564,8141,596,6942,246,8321,203,0511,161,6771,344,5881,232,9431,329,199750,541806,111872,025934,926878,7131,069,390908,2781,144,6902,242,3162,354,6392,147,7301,801,0411,918,4841,974,3241,867,6091,733,6671,700,1641,662,9691,569,1411,279,5811,342,0851,355,0511,278,1091,182,1881,249,1071,247,0201,171,3011,118,5591,348,1991,371,1471,452,5111,308,7751,440,1761,401,7271,346,9691,264,1141,464,3901,462,6511,733,0111,874,0262,257,3572,270,3662,188,8022,297,9342,358,3772,462,8653,111,9862,541,2372,562,5402,112,6902,127,0042,011,5511,869,4591,887,1811,840,5521,256,2811,153,071628,885589,199
   > Total Current Liabilities 
584,308
622,215
999,572
1,149,950
1,731,234
1,788,028
1,751,211
1,965,607
1,866,293
1,863,357
2,296,925
2,276,578
2,828,294
2,397,790
2,093,194
2,232,394
2,123,138
2,204,015
2,191,140
1,821,614
1,704,289
1,434,201
1,419,981
1,234,233
1,317,110
1,371,888
1,409,864
1,283,611
1,427,365
1,343,269
1,321,343
1,104,304
1,157,055
1,233,571
1,235,853
1,153,606
1,236,233
1,311,240
1,265,011
1,203,044
1,493,875
1,585,709
1,613,898
1,651,844
1,784,867
1,892,206
1,798,115
1,682,295
2,028,950
2,234,624
2,124,147
1,028,855
793,438
956,870
767,460
826,350
765,756
701,305
647,955
1,104,249
1,012,706
1,139,332
961,257
1,015,223
2,017,630
1,371,756
1,345,661
1,209,164
1,419,802
2,132,160
2,159,266
2,128,002
2,439,662
2,449,252
2,420,428
2,341,453
2,355,320
2,705,733
2,530,552
2,670,031
2,626,470
2,827,571
2,434,896
2,730,944
2,693,099
2,973,712
3,371,131
3,011,828
2,883,878
3,362,075
2,978,540
3,162,113
3,162,1132,978,5403,362,0752,883,8783,011,8283,371,1312,973,7122,693,0992,730,9442,434,8962,827,5712,626,4702,670,0312,530,5522,705,7332,355,3202,341,4532,420,4282,449,2522,439,6622,128,0022,159,2662,132,1601,419,8021,209,1641,345,6611,371,7562,017,6301,015,223961,2571,139,3321,012,7061,104,249647,955701,305765,756826,350767,460956,870793,4381,028,8552,124,1472,234,6242,028,9501,682,2951,798,1151,892,2061,784,8671,651,8441,613,8981,585,7091,493,8751,203,0441,265,0111,311,2401,236,2331,153,6061,235,8531,233,5711,157,0551,104,3041,321,3431,343,2691,427,3651,283,6111,409,8641,371,8881,317,1101,234,2331,419,9811,434,2011,704,2891,821,6142,191,1402,204,0152,123,1382,232,3942,093,1942,397,7902,828,2942,276,5782,296,9251,863,3571,866,2931,965,6071,751,2111,788,0281,731,2341,149,950999,572622,215584,308
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
34,400
59,000
59,000
40,000
57,300
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000057,30040,00059,00059,00034,40000000000000000000000000000000000000000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
34,400
59,000
59,000
40,000
57,300
56,300
53,800
45,000
0
0
0
2,330
4,745
6,194
0
3,564
4,946
6,826
11,376
14,849
29,969
29,96914,84911,3766,8264,9463,56406,1944,7452,33000045,00053,80056,30057,30040,00059,00059,00034,40000000000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
153,287
192,787
391,149
499,711
846,483
901,450
853,579
829,150
884,030
941,557
1,099,183
1,041,828
1,327,983
1,094,393
1,069,798
924,630
940,272
947,211
955,479
745,107
747,979
680,643
731,530
624,177
668,300
744,893
772,528
592,993
718,190
637,473
656,956
440,516
602,399
615,183
662,707
518,108
615,760
644,082
686,420
568,349
713,969
726,749
850,087
718,297
844,539
885,640
903,295
959,931
1,183,568
1,093,431
1,065,972
428,544
428,112
470,339
460,512
488,412
380,499
338,588
340,762
400,738
372,449
399,825
395,595
395,673
436,695
555,426
553,775
469,243
447,737
520,389
526,911
547,289
564,597
599,065
604,191
690,755
579,837
657,652
722,481
848,048
782,709
820,726
845,820
847,402
734,515
654,661
772,898
744,518
809,706
803,663
706,397
722,509
722,509706,397803,663809,706744,518772,898654,661734,515847,402845,820820,726782,709848,048722,481657,652579,837690,755604,191599,065564,597547,289526,911520,389447,737469,243553,775555,426436,695395,673395,595399,825372,449400,738340,762338,588380,499488,412460,512470,339428,112428,5441,065,9721,093,4311,183,568959,931903,295885,640844,539718,297850,087726,749713,969568,349686,420644,082615,760518,108662,707615,183602,399440,516656,956637,473718,190592,993772,528744,893668,300624,177731,530680,643747,979745,107955,479947,211940,272924,6301,069,7981,094,3931,327,9831,041,8281,099,183941,557884,030829,150853,579901,450846,483499,711391,149192,787153,287
       Other Current Liabilities 
142,191
180,108
188,830
275,710
370,204
360,590
368,406
438,599
400,475
313,182
335,924
358,980
487,295
398,537
395,686
422,324
454,646
453,444
427,231
358,707
282,810
323,558
330,951
291,556
334,310
322,995
333,336
379,618
398,175
423,296
381,887
322,288
284,656
374,388
333,146
357,498
375,473
422,158
327,798
355,289
408,864
442,542
364,671
532,798
557,073
626,566
509,820
427,364
430,382
700,193
597,175
390,311
365,326
486,532
306,948
337,938
385,256
362,717
307,192
673,511
630,258
739,507
565,662
619,551
1,580,936
816,330
791,886
739,920
972,065
706,808
1,518,775
583,654
328,194
296,534
197,686
548,778
1,527,262
680,496
1,545,512
672,613
1,686,077
678,384
1,366,668
578,289
57,204
884,829
2,320,155
57,204
57,204
1,022,222
19,428
20,799
20,79919,4281,022,22257,20457,2042,320,155884,82957,204578,2891,366,668678,3841,686,077672,6131,545,512680,4961,527,262548,778197,686296,534328,194583,6541,518,775706,808972,065739,920791,886816,3301,580,936619,551565,662739,507630,258673,511307,192362,717385,256337,938306,948486,532365,326390,311597,175700,193430,382427,364509,820626,566557,073532,798364,671442,542408,864355,289327,798422,158375,473357,498333,146374,388284,656322,288381,887423,296398,175379,618333,336322,995334,310291,556330,951323,558282,810358,707427,231453,444454,646422,324395,686398,537487,295358,980335,924313,182400,475438,599368,406360,590370,204275,710188,830180,108142,191
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
268,912
258,940
252,931
258,852
252,654
246,745
240,049
369,470
500,299
474,633
508,900
468,555
484,810
463,022
739,698
741,063
753,063
522,857
525,053
479,074
479,074525,053522,857753,063741,063739,698463,022484,810468,555508,900474,633500,299369,470240,049246,745252,654258,852252,931258,940268,912000000000000000000000000000000000000000000000000000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-34,400
-59,000
-59,000
-40,000
-57,300
0
0
0
0
117,422
91,381
104,764
35,432
61,897
36,798
53,575
32,932
56,452
29,437
39,471
29,950
29,95039,47129,43756,45232,93253,57536,79861,89735,432104,76491,381117,4220000-57,300-40,000-59,000-59,000-34,40000000000000000000000000000000000000000000000000000000000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,710
710
710
14,003
14,003
14,003
14,003
14,003
14,003
14,003
14,003
710
1,256
710
5,213
4,667
5,213
4,667
2,213
1,667
1,6672,2134,6675,2134,6675,2137101,25671014,00314,00314,00314,00314,00314,00314,00314,0037107107,710000000000000000000000000000000000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
426,968
452,663
481,730
514,040
533,405
565,606
574,943
598,854
605,151
631,131
569,376
606,086
589,327
611,173
723,661
0
728,986
722,348
786,152
0
867,362
0
0
00867,3620786,152722,348728,9860723,661611,173589,327606,086569,376631,131605,151598,854574,943565,606533,405514,040481,730452,663426,968000000000000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
757,144
790,559
824,994
1,282,758
1,324,018
1,386,194
1,421,661
1,404,196
1,444,244
1,506,126
1,552,586
1,491,803
1,520,165
1,509,122
1,528,186
1,538,397
1,572,836
1,692,015
1,717,751
1,727,870
1,771,421
1,814,401
1,779,200
1,815,544
1,901,841
1,919,335
1,988,183
2,197,473
2,306,337
2,890,143
2,982,123
3,079,545
3,225,856
3,255,658
3,367,642
3,470,517
3,645,374
3,632,822
3,770,490
3,863,151
4,054,589
4,027,693
4,135,187
4,257,680
4,477,721
4,375,491
4,515,691
4,653,606
4,815,506
4,807,522
4,990,833
5,332,737
5,482,922
5,452,536
5,566,839
5,679,125
5,848,745
6,012,011
6,110,862
6,106,660
6,288,888
6,405,219
6,573,231
6,686,214
6,921,609
7,137,032
7,340,913
7,456,791
7,757,234
7,455,825
7,712,219
7,839,918
8,169,418
8,187,560
8,467,747
8,602,508
8,877,359
8,839,524
9,158,781
9,294,106
9,564,036
9,570,537
9,865,707
9,905,496
9,956,374
9,892,936
9,819,720
10,022,611
10,408,710
10,531,771
10,846,442
11,090,411
11,090,41110,846,44210,531,77110,408,71010,022,6119,819,7209,892,9369,956,3749,905,4969,865,7079,570,5379,564,0369,294,1069,158,7818,839,5248,877,3598,602,5088,467,7478,187,5608,169,4187,839,9187,712,2197,455,8257,757,2347,456,7917,340,9137,137,0326,921,6096,686,2146,573,2316,405,2196,288,8886,106,6606,110,8626,012,0115,848,7455,679,1255,566,8395,452,5365,482,9225,332,7374,990,8334,807,5224,815,5064,653,6064,515,6914,375,4914,477,7214,257,6804,135,1874,027,6934,054,5893,863,1513,770,4903,632,8223,645,3743,470,5173,367,6423,255,6583,225,8563,079,5452,982,1232,890,1432,306,3372,197,4731,988,1831,919,3351,901,8411,815,5441,779,2001,814,4011,771,4211,727,8701,717,7511,692,0151,572,8361,538,3971,528,1861,509,1221,520,1651,491,8031,552,5861,506,1261,444,2441,404,1961,421,6611,386,1941,324,0181,282,758824,994790,559757,144
   Common Stock
305,695
305,695
305,695
339,289
339,289
441,076
441,076
441,076
441,076
441,076
441,076
441,076
441,076
441,076
441,076
441,076
441,076
441,076
441,076
441,076
441,076
441,076
441,076
441,076
441,076
441,076
441,076
441,076
441,076
476,413
476,413
476,413
476,413
476,413
571,696
571,696
571,696
571,696
571,696
571,696
571,696
571,696
571,696
571,696
571,696
571,696
571,696
571,696
571,696
571,696
571,696
571,696
571,696
571,696
571,696
571,696
571,696
571,696
571,696
724,471
724,471
724,471
724,471
724,471
724,471
724,471
869,365
869,365
869,365
869,365
1,043,238
1,043,238
1,043,238
1,043,238
1,043,238
1,043,238
1,043,238
1,043,238
1,043,238
1,043,238
1,043,238
1,043,238
1,043,238
1,043,238
0
1,043,238
1,043,238
1,043,154
0
1,043,127
0
0
001,043,12701,043,1541,043,2381,043,23801,043,2381,043,2381,043,2381,043,2381,043,2381,043,2381,043,2381,043,2381,043,2381,043,2381,043,2381,043,2381,043,2381,043,238869,365869,365869,365869,365724,471724,471724,471724,471724,471724,471724,471571,696571,696571,696571,696571,696571,696571,696571,696571,696571,696571,696571,696571,696571,696571,696571,696571,696571,696571,696571,696571,696571,696571,696571,696571,696476,413476,413476,413476,413476,413441,076441,076441,076441,076441,076441,076441,076441,076441,076441,076441,076441,076441,076441,076441,076441,076441,076441,076441,076441,076441,076441,076441,076441,076339,289339,289305,695305,695305,695
   Retained Earnings 
136,804
132,781
179,023
171,446
212,706
274,882
310,348
244,290
284,290
328,417
374,877
289,015
317,377
306,264
325,231
326,316
359,770
478,893
503,992
462,465
508,012
552,809
519,123
526,987
613,285
625,560
694,908
980,834
1,088,970
1,084,040
1,176,020
1,249,446
1,395,496
1,425,298
1,441,999
1,511,768
1,686,624
1,673,726
1,811,395
1,867,399
2,058,836
2,032,055
2,139,549
2,215,991
2,436,032
2,333,802
2,474,002
2,610,868
2,772,767
2,765,329
2,948,639
3,296,900
3,751,977
3,721,591
3,835,894
3,948,180
4,113,601
4,279,988
4,377,968
4,721,278
4,903,674
5,020,774
5,188,767
5,301,462
5,536,303
5,750,548
5,809,721
5,927,458
6,227,903
6,438,173
6,520,264
6,649,678
6,515,931
6,534,159
6,814,307
7,413,738
7,688,715
7,650,832
7,969,915
8,101,756
8,371,101
8,376,948
8,671,392
8,718,035
8,528,388
8,955,829
8,897,530
9,042,026
8,933,316
9,518,341
9,338,163
9,670,626
9,670,6269,338,1639,518,3418,933,3169,042,0268,897,5308,955,8298,528,3888,718,0358,671,3928,376,9488,371,1018,101,7567,969,9157,650,8327,688,7157,413,7386,814,3076,534,1596,515,9316,649,6786,520,2646,438,1736,227,9035,927,4585,809,7215,750,5485,536,3035,301,4625,188,7675,020,7744,903,6744,721,2784,377,9684,279,9884,113,6013,948,1803,835,8943,721,5913,751,9773,296,9002,948,6392,765,3292,772,7672,610,8682,474,0022,333,8022,436,0322,215,9912,139,5492,032,0552,058,8361,867,3991,811,3951,673,7261,686,6241,511,7681,441,9991,425,2981,395,4961,249,4461,176,0201,084,0401,088,970980,834694,908625,560613,285526,987519,123552,809508,012462,465503,992478,893359,770326,316325,231306,264317,377289,015374,877328,417284,290244,290310,348274,882212,706171,446179,023132,781136,804
   Capital Surplus 00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
62
68
-2,387
-2,031
-2,116
-2,078
-3,857
-3,983
-3,935
-3,761
-277
308
962
1,688
-5,167
0
-4,537
-3,666
0
0
756
0
0
0075600-3,666-4,5370-5,1671,688962308-277-3,761-3,935-3,983-3,857-2,078-2,116-2,031-2,3876862000000000000000000000000000000000000000000000000000000000000000000000



Balance Sheet

Currency in CNY. All numbers in thousands.




Cash Flow

Currency in CNY. All numbers in thousands.




Income Statement

Currency in CNY. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue10,222,132
Cost of Revenue-4,575,802
Gross Profit5,646,3305,646,330
 
Operating Income (+$)
Gross Profit5,646,330
Operating Expense-8,673,804
Operating Income1,548,329-3,027,474
 
Operating Expense (+$)
Research Development561,459
Selling General Administrative2,847,083
Selling And Marketing Expenses0
Operating Expense8,673,8043,408,542
 
Net Interest Income (+$)
Interest Income52,927
Interest Expense-14,069
Other Finance Cost-1,340
Net Interest Income37,518
 
Pretax Income (+$)
Operating Income1,548,329
Net Interest Income37,518
Other Non-Operating Income Expenses0
Income Before Tax (EBT)1,566,5231,548,329
EBIT - interestExpense = -14,069
1,333,029
1,347,099
Interest Expense14,069
Earnings Before Interest and Taxes (EBIT)01,580,592
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax1,566,523
Tax Provision-240,615
Net Income From Continuing Ops1,325,9081,325,908
Net Income1,333,029
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-37,518
 

Technical Analysis of China Resources Double-Crane Pharmaceutical Co Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of China Resources Double-Crane Pharmaceutical Co Ltd. The general trend of China Resources Double-Crane Pharmaceutical Co Ltd is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine China Resources Double-Crane Pharmaceutical Co Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of China Resources Double-Crane Pharmaceutical Co Ltd.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 21.55 < 21.84 < 24.43.

The bearish price targets are: 20.94 > 19.20 > 18.93.

Tweet this
China Resources Double-Crane Pharmaceutical Co Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of China Resources Double-Crane Pharmaceutical Co Ltd. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

China Resources Double-Crane Pharmaceutical Co Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of China Resources Double-Crane Pharmaceutical Co Ltd. The current macd is 0.18884337.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the China Resources Double-Crane Pharmaceutical Co Ltd price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for China Resources Double-Crane Pharmaceutical Co Ltd. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the China Resources Double-Crane Pharmaceutical Co Ltd price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
China Resources Double-Crane Pharmaceutical Co Ltd Daily Moving Average Convergence/Divergence (MACD) ChartChina Resources Double-Crane Pharmaceutical Co Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of China Resources Double-Crane Pharmaceutical Co Ltd. The current adx is 9.5660616.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy China Resources Double-Crane Pharmaceutical Co Ltd shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
China Resources Double-Crane Pharmaceutical Co Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of China Resources Double-Crane Pharmaceutical Co Ltd. The current sar is 19.29.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
China Resources Double-Crane Pharmaceutical Co Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of China Resources Double-Crane Pharmaceutical Co Ltd. The current rsi is 56.08. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
China Resources Double-Crane Pharmaceutical Co Ltd Daily Relative Strength Index (RSI) ChartChina Resources Double-Crane Pharmaceutical Co Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of China Resources Double-Crane Pharmaceutical Co Ltd. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the China Resources Double-Crane Pharmaceutical Co Ltd price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
China Resources Double-Crane Pharmaceutical Co Ltd Daily Stochastic Oscillator ChartChina Resources Double-Crane Pharmaceutical Co Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of China Resources Double-Crane Pharmaceutical Co Ltd. The current cci is 132.41.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
China Resources Double-Crane Pharmaceutical Co Ltd Daily Commodity Channel Index (CCI) ChartChina Resources Double-Crane Pharmaceutical Co Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of China Resources Double-Crane Pharmaceutical Co Ltd. The current cmo is 14.59.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
China Resources Double-Crane Pharmaceutical Co Ltd Daily Chande Momentum Oscillator (CMO) ChartChina Resources Double-Crane Pharmaceutical Co Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of China Resources Double-Crane Pharmaceutical Co Ltd. The current willr is -21.3740458.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that China Resources Double-Crane Pharmaceutical Co Ltd is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
China Resources Double-Crane Pharmaceutical Co Ltd Daily Williams %R ChartChina Resources Double-Crane Pharmaceutical Co Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of China Resources Double-Crane Pharmaceutical Co Ltd.

China Resources Double-Crane Pharmaceutical Co Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of China Resources Double-Crane Pharmaceutical Co Ltd. The current atr is 0.71304079.

China Resources Double-Crane Pharmaceutical Co Ltd Daily Average True Range (ATR) ChartChina Resources Double-Crane Pharmaceutical Co Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of China Resources Double-Crane Pharmaceutical Co Ltd. The current obv is 1,603,946,731.

China Resources Double-Crane Pharmaceutical Co Ltd Daily On-Balance Volume (OBV) ChartChina Resources Double-Crane Pharmaceutical Co Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of China Resources Double-Crane Pharmaceutical Co Ltd. The current mfi is 50.03.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
China Resources Double-Crane Pharmaceutical Co Ltd Daily Money Flow Index (MFI) ChartChina Resources Double-Crane Pharmaceutical Co Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for China Resources Double-Crane Pharmaceutical Co Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-24CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-28WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-01STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-07WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-08RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-15RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-20WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-25STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-02CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-22BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-23RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-24MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-31DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-19WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-29WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-01CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-04BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-25WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-10DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-15CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-22BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-04-23STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

China Resources Double-Crane Pharmaceutical Co Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of China Resources Double-Crane Pharmaceutical Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5056.075
Ma 20Greater thanMa 5020.493
Ma 50Greater thanMa 10020.157
Ma 100Greater thanMa 20019.287
OpenGreater thanClose21.300
Total5/5 (100.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of China Resources Double-Crane Pharmaceutical Co Ltd with someone you think should read this too:
  • Are you bullish or bearish on China Resources Double-Crane Pharmaceutical Co Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about China Resources Double-Crane Pharmaceutical Co Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about China Resources Double-Crane Pharmaceutical Co Ltd

I send you an email if I find something interesting about China Resources Double-Crane Pharmaceutical Co Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about China Resources Double-Crane Pharmaceutical Co Ltd.

Receive notifications about China Resources Double-Crane Pharmaceutical Co Ltd in your mailbox!